brand drug price commentari somewhat similar fashion mck recent
earn call management address concern regard brand inflat environ
possibl chang gross net price management believ switch gross
net price like happen time believ abl re-contract
custom maintain current econom brand inflat
compani acknowledg activ price rollback management believ abl
go back manufactur discuss/renegoti contract order properli
compens valu management expect bottom
brand inflat rang given recent activ period includ
key januari brand inflat cycl management state still may visibl
trend provid guidanc day thu may alloc wider
rang guidanc relat brand inflat econom
gener price gener price management indic deflat eas
may remain level still overal move forward
encourag continu gener mfr sku ration may help improv
price move forward although note teva larg gener manufactur report
earn indic poor sale due continu price eros us busi
tweak estim model pg altogeth address key
point management provid explicit commentari regard ep beyond
look forward grow oper profit earli
plan process made consciou decis done plan
provid guidanc better expect quarter rais
full year ep rais ep
restart memphi pharmedium facil maintain
conserv stanc regard januari brand inflat cycl remain ew
pt base price-to-earnings ep estim
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight gain
share via largest custom walgreen
compani continu face headwind throughout
relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead multipl ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
pharmedium memphi facil open product commerci
shipment expect begin month august exact time ramp
facil remain unclear time posit facil open
management announc renew contract earli margin
headwind time length contract disclos
relat soft segment compani note
take longer expect migrat client new fusion platform
impact lash busi separ slightli lower growth relat mwiv
 servic profit profit profit marginsdown bpstax changeshar repurchaseoffset dilutionoffset dilutionoffset dilutionoffset dilutionoffset milgener new genericscontribut new genericscontribut new genericscontribut new genericscontribut new genericssimilar prior yearsimilar prior yearsimilar prior yearsimilar prior yearsimilar prior yearno signific contribut biosimsno signific contribut biosimsno signific contribut biosimsno signific contribut biosimsno signific contribut biosimshd smith acquisit includedhd smith acquisit includedbottom end ep guidancebottom end ep guidanc barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
 annual revenu model mil abcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit barclay corp
 annual incom statement distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
